A method for detecting the concentration of 2,4-disubstituted-5-fluoropyrimidine derivatives in plasma
The pretreatment step of finasteride internal standard was solved by liquid chromatography-tandem mass spectrometry combined with the pretreatment step of finasteride internal standard, and the problem of detection of 2,4-disubstituted-5-fluoropyrimidine derivative concentration in plasma was achieved, achieving efficient and accurate analysis , supports its application in clinical research, and improves the safety and efficiency of research.
Patent Information
- Application Number
- CN202411204334.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-08-30
AI Technical Summary
The existing technology cannot effectively and accurately detect the concentration of 2,4-disubstituted-5-fluoropyrimidine derivatives in plasma, and lacks simple, fast and highly sensitive analytical methods, which limits its application in clinical research.
The concentration of 2,4-disubstituted-5-fluoropyrimidine derivatives in plasma was detected by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The concentration of 2,4-disubstituted-5-fluoropyrimidine derivatives was added through the pretreatment step, and the XBridge was used to add finasteride as an internal standard. ®BEH C8 chromatographic column and electrospray ion source are used for detection, setting appropriate chromatographic and mass spectrometry conditions for efficient analysis.
Achieve the detection of 2,4-disubstituted-5-fluoropyrimidine derivatives in plasma with high efficiency, accuracy and sensitivity, supporting its application in non-clinical and clinical studies, reducing subjects' medication dosage and whole blood collection improves the safety and compliance of clinical studies.
Smart Images

Figure CN118707005B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of drug analysis, and specifically relates to a method for detecting the concentration of 2,4-disubstituted-5-fluoropyrimidine derivatives in plasma. Background Art
[0002] The chemical structure of the 2,4-disubstituted-5-fluoropyrimidine derivatives of the present invention is as follows:
[0003] , whose CAS number is 2968523-32-0, is a new drug molecule, which is compound 7a reported in patent CN116514779A. It can act on the HIPK2 target to resist renal fibrosis, reduce renal damage and renal interstitial fibrosis deposition.
[0004] Therapeutic drug monitoring and clinical research require the measurement of blood drug concentrations in subjects or patients to study their pharmacokinetic behavior. In order to accelerate the clinical application of 2,4-disubstituted-5-fluoropyrimidine derivatives (CAS No.: 2968523-32-0) and their pharmaceutically acceptable salts, a simple, accurate, rapid and highly sensitive bioanalytical method is needed.
[0005] So far, there are no related literature and patent reports on methods for detecting 2,4-disubstituted-5-fluoropyrimidine derivatives (CAS No.: 2968523-32-0) and their pharmaceutically acceptable salts in plasma. Therefore, it is necessary to develop an analytical method with simple pretreatment operation and taking into account sensitivity, accuracy, and analysis speed, so as to be suitable for the accurate analysis of large batches of samples in clinical research of drugs related to 2,4-disubstituted-5-fluoropyrimidine derivatives (CAS No.: 2968523-32-0). Summary of the invention
[0006] In order to solve the above technical problems, the purpose of the present invention is to provide a method for detecting the concentration of 2,4-disubstituted-5-fluoropyrimidine derivatives in plasma.
[0007] To achieve the above object, the present invention adopts the following technical solution:
[0008] A method for detecting the concentration of 2,4-disubstituted-5-fluoropyrimidine derivatives in plasma, comprising the following steps:
[0009] (1) Pretreatment: adding an organic solution containing an internal standard to the plasma sample to precipitate protein, taking the supernatant after centrifugation, and diluting it with water to obtain the test sample; the internal standard is finasteride, and the organic solution containing the internal standard includes a methanol solution containing finasteride and / or an acetonitrile solution containing finasteride;
[0010] (2) Sample injection detection: The sample was injected and tested by liquid chromatography-tandem mass spectrometry (LC-MS / MS), where the chromatographic conditions and mass spectrometry conditions were as follows:
[0011] Chromatographic conditions: XBridge®BEH C8 column, gradient elution, autosampler temperature 0-10°C, column temperature 30-45°C, mobile phase A is an aqueous solution containing 0.01% formic acid and 5 mM ammonium formate, mobile phase B is methanol;
[0012] Mass spectrometry conditions: electrospray ionization (ESI) source, positive ion detection, multiple reaction monitoring (MRM) mode, spray voltage 5500 V, ion source temperature 500 °C.
[0013] It can be understood that the present invention does not use isotopes as internal standards, but uses finasteride as a non-isotopic internal standard, and verifies the stability of finasteride as a non-isotopic internal standard, which does not interfere with the concentration detection of the 2,4-disubstituted-5-fluoropyrimidine derivative to be tested. In addition, directly using an organic solution containing an internal standard for protein precipitation can simplify the analysis experiment operation.
[0014] In some embodiments, in the pretreatment step, the volume of the plasma sample is 20 to 100 μL, the volume ratio of the plasma sample to the organic solution containing the internal standard is 1:1 to 1:15, and the content of the 2,4-disubstituted-5-fluoropyrimidine derivative to be tested in the plasma sample is 1.000 to 500.0 ng / mL. Further, when the volume of the plasma sample is 20 μL, the volume ratio of the plasma sample to the organic solution containing the internal standard is preferably 1:10.
[0015] In some embodiments, in the pretreatment step, the supernatant taken after centrifugation is diluted with water, so that the sample is not easy to volatilize, which is beneficial to the preservation of the sample and the accuracy of the detection; the amount of water added is 0.5 to 2 times the volume of the supernatant, and preferably the amount of water added is equal to the volume of the supernatant.
[0016] In some embodiments, in the pretreatment step, the concentration of finasteride in the organic solution containing the internal standard is 2.000 ng / mL.
[0017] In some embodiments, in the chromatographic conditions, the specifications of the XBridge® BEH C8 chromatographic column are 2.1 mm×50 mm, 2.5 µm.
[0018] In some embodiments, in the chromatographic conditions, the temperature of the autosampler is 5°C and the column temperature is 40°C.
[0019] In some embodiments, in the chromatographic conditions, the gradient elution program is set as follows:
[0020] , The percentages of mobile phase A and mobile phase B are by volume.
[0021] In some embodiments, in the mass spectrometry conditions, gas 1 (Gas1) is 50 psi, gas 2 (Gas2) is 55 psi, curtain gas (Curtain Gas) is 35 psi, collision activated dissociation is 8 psi, and the residence time is 300 ms; the quantitative analysis ion pair m / z of the 2,4-disubstituted-5-fluoropyrimidine derivative to be tested is 405.3→134.2, the collision energy (CE) is 60 eV, and the declustering voltage (DP) is 130 V; the quantitative analysis ion pair m / z of the internal standard finasteride is 373.1→305.2, the collision energy (CE) is 40 eV, and the declustering voltage (DP) is 100 V.
[0022] By means of the above scheme, the present invention has at least the following advantages:
[0023] (1) The detection method described in the present invention is the only method disclosed so far for detecting the concentration of 2,4-disubstituted-5-fluoropyrimidine derivatives (CAS No.: 2968523-32-0) in plasma. The LC-MS / MS method has high analysis efficiency and can be used to support non-clinical and clinical research work on this new drug molecule.
[0024] (2) The detection method described in the present invention has achieved a major breakthrough in the pretreatment process of LC-MS / MS analysis. Through the simple operation of only one-step extraction and one-step dilution, as well as the easy preservation of the extracted samples, it provides an efficient, stable and economical solution for the routine determination of large quantities of clinical samples.
[0025] (3) The detection method described in the present invention has high sensitivity. When the amount of plasma sample is only 20 µL, the lower limit of quantification of the 2,4-disubstituted-5-fluoropyrimidine derivative to be tested is 1.000 ng / mL. The detection limit is calculated to be 0.1515 ng / mL based on the signal-to-noise ratio of 3. The amount of the analyte on the detection limit column is 0.1 pg based on the dilution factor of 20 and the injection volume of 2 µL. This can reduce the amount of medication and the amount of whole blood collected by the subjects, which is beneficial to increase the safety of clinical research and the compliance of the subjects. In addition, the linear range is reasonably selected (1.000-500.0 ng / mL), which can accurately determine the concentration of the test compound in plasma.
[0026] The above description is only an overview of the technical solution of the present invention. In order to more clearly understand the technical means of the present invention and implement it according to the contents of the specification, the following is a detailed description of the preferred embodiments of the present invention in conjunction with the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 is a product ion scanning mass spectrum of the 2,4-disubstituted-5-fluoropyrimidine derivative to be tested;
[0028] Figure 2 It is the product ion scanning mass spectrum of finasteride;
[0029] Figure 3 is the MRM chromatogram of the 2,4-disubstituted-5-fluoropyrimidine derivative to be tested and finasteride in the blank plasma sample, wherein a is the MRM chromatogram of the 2,4-disubstituted-5-fluoropyrimidine derivative to be tested, and b is the MRM chromatogram of finasteride;
[0030] Figure 4 is the MRM chromatogram of the 2,4-disubstituted-5-fluoropyrimidine derivative to be tested and finasteride in the lower limit of quantification sample, wherein a is the MRM chromatogram of the 2,4-disubstituted-5-fluoropyrimidine derivative to be tested, and b is the MRM chromatogram of finasteride;
[0031] Figure 5 This is a drug concentration-time curve of SD rats after a single intravenous administration of 5 mg / kg of the 2,4-disubstituted-5-fluoropyrimidine derivative to be tested. DETAILED DESCRIPTION
[0032] The present invention is further described in detail in conjunction with the following specific examples and drawings, and the protection content of the present invention is not limited to the following examples. Without departing from the spirit and scope of the inventive concept, changes and advantages that can be thought of by those skilled in the art are included in the present invention, and the attached claims are the scope of protection. The process, conditions, reagents, experimental methods, etc. for implementing the present invention, except for the contents specifically mentioned below, are all common knowledge and common common sense in the art, and the present invention does not specifically limit the content.
[0033] In the present invention, unless otherwise specified, the percentages and ratios mentioned in the reagents are weight percentages and weight ratios.
[0034] In the present invention, the unit "mM" used represents millimole per liter (mmol / L), and "v / v" and "v / v / v / v" used represent volume ratio.
[0035] Example 1 Detection of the concentration of 2,4-disubstituted-5-fluoropyrimidine derivatives in plasma
[0036] 1 Materials
[0037] 1.1 Instruments
[0038] Chromatograph: LC-30AD fast liquid chromatography system, Shimadzu Corporation, Japan.
[0039] Mass spectrometer: Model 6500+ triple quadrupole tandem mass spectrometer, Sciex, Canada.
[0040] 1.2 Reference substances and reagents
[0041] 2,4-disubstituted-5-fluoropyrimidine derivative reference substance to be tested: prepared by oneself with reference to the prior art (the preparation method of compound 7a involved in patent CN116514779A), purity determination and calibration are performed, CAS number is 2968523-32-0, content is 92.80%, and it is stored in a cold place away from light and moisture.
[0042] Finasteride reference substance: purchased from China Food and Drug Inspection Institute, content 99.5%, batch number 100611-202204, stored in a light-proof and sealed place at 10-30°C.
[0043] Methanol, acetonitrile, and isopropanol were purchased from Sigma, USA, and were all HPLC grade.
[0044] Formic acid and ammonium formate: purchased from ACS, both are HPLC grade.
[0045] Ammonia: purchased from Merck, HPLC grade.
[0046] Ultrapure water (18.2 mΩ, TOC ≤ 50 ppb) was prepared by a Milli-Q ultrapure water system.
[0047] 2 Methods
[0048] 2.1 Solution and sample preparation
[0049] Standard series samples: Accurately weigh an appropriate amount of the 2,4-disubstituted-5-fluoropyrimidine derivative reference substance to be tested, dissolve it in methanol: water (1:1, v / v) and make up to volume to prepare a stock solution with a concentration of about 10.00 mg / mL. Accurately pipette an appropriate amount of the stock solution, dilute it step by step with methanol: water (1:1, v / v) to obtain a mixed standard series solution, and dilute the standard series solution with blank plasma to prepare a standard series of samples. The concentration range of the 2,4-disubstituted-5-fluoropyrimidine derivative to be tested is 1.000~500.0ng / mL.
[0050] Quality control (QC) samples: Mixed quality control samples of 2,4-disubstituted-5-fluoropyrimidine derivatives to be tested were prepared in a similar manner to the standard series samples at three concentration levels. The lower limit of quantification concentration was 1.000 ng / mL, the low quality control (LQC) concentration was 3.000 ng / mL, the medium quality control (MQC) concentration was 25.00 ng / mL, and the high quality control (HQC) concentration was 375.0 ng / mL.
[0051] Organic solution containing internal standard: Accurately weigh the finasteride reference substance, dissolve it in methanol and make up to volume to prepare an internal standard stock solution with a concentration of about 5.000 mg / mL. Accurately pipette an appropriate amount of the above internal standard stock solution and dilute it with acetonitrile to obtain an internal standard working solution with a finasteride concentration of 2.000 ng / mL.
[0052] 2.2 Plasma sample pretreatment
[0053] The pretreatment steps of plasma samples are shown in Table 1.
[0054] Table 1 Plasma sample pretreatment steps
[0055]
[0056] 2.3 Chromatographic and mass spectrometry conditions
[0057] Chromatography, the injection volume used was 2.0 μL, and the specific chromatographic separation conditions are shown in Table 2, where the percentages of mobile phase A and mobile phase B are volume percentages.
[0058] Table 2 Chromatographic separation conditions
[0059]
[0060]
[0061] Mass spectrometry: The specific mass spectrometry detection conditions are shown in Table 3. The entrance voltage (EP) was set to 10.0 V, and the exit voltage (CXP) of the collision cell was set to 10.0 V.
[0062] Table 3 Mass spectrometry detection conditions.
[0063]
[0064] The daughter ion scanning mass spectra of the 2,4-disubstituted-5-fluoropyrimidine derivative to be tested and the daughter ion scanning mass spectra of finasteride are as follows: Figure 1 and Figure 2 As shown, they all have stable mass spectrometric responses and are not easily affected by matrix effects.
[0065] 2.4 Methodological validation
[0066] The method was validated according to the guidelines of Chinese Pharmacopoeia 9012, including stability, selectivity, linearity, accuracy, precision, recovery, matrix effect, etc.
[0067] Selectivity
[0068] Six blank plasmas from different sources and their respective prepared lower limit of quantitation samples were processed and injected for analysis. The peak area of the chromatographic co-eluting interferents must be less than 20% of the peak area of the lower limit of quantitation analyte and less than 5% of the peak area of the internal standard.
[0069] Standard curve
[0070] The linear regression equation (weight factor W = 1 / x) is calculated by taking the theoretical concentration of the analyte as the horizontal axis (x) and the peak area ratio of the analyte to the internal standard as the vertical axis (y). 2 ). For method validation, two samples of the standard curve were analyzed for each analytical batch.
[0071] Precision and Accuracy
[0072] For method validation, six samples of four concentrations of quality control samples were measured for each analytical batch (i.e., n=6). The intra-batch and inter-batch precision of the quantitative lower limit calculated by relative standard deviation (RSD) was acceptable only when it was less than 20%, and the accuracy calculated by relative deviation (RE) was acceptable only when it was between -20% and 20%. The intra-batch and inter-batch precision of each component of the QC samples at other concentration levels was acceptable only when it was less than 15%, and the accuracy was acceptable only when it was between -15% and 15%.
[0073] stability
[0074] When investigating the stability of the analyte in plasma samples, LQC samples and HQC samples were placed at different temperatures and environments, and six samples were analyzed after the placement (i.e., n=6). A total of four placement conditions were investigated, namely: 28 hours at room temperature, 198 hours at 4°C after preparation, 5 freeze-thaw cycles (from -80°C to room temperature), and 73 days at -80°C.
[0075] Recovery rate
[0076] Take 20 µL of blank plasma, extract protein with methanol and / or acetonitrile solution (without internal standard), add the test compound and internal standard to make the final concentration the same as that of LQC sample, MQC sample and HQC sample, and inject for detection. Extract 6 copies of LQC sample, MQC sample and HQC sample respectively, and inject for determination. Calculate the extraction recovery rate by the peak area ratio of the two treatment methods.
[0077] Matrix Effects
[0078] Six blank plasma samples from different sources were taken, and after protein precipitation and extraction with methanol and / or acetonitrile solution (without internal standard), the test compound and internal standard were added to make the final concentration the same as that of LQC sample and HQC sample, respectively. After vortex mixing, the samples were injected for detection. Water was taken to replace plasma and treated as above. The matrix factor was calculated by the peak area ratio obtained by the two methods, and the matrix effect was evaluated by the RSD of the matrix factor normalized by the internal standard. It was acceptable only if it was less than 15%.
[0079] 3 Results and discussion
[0080] 3.1 Methodological validation
[0081] Selectivity of method
[0082] like Figure 3 and Figure 4 As shown, the retention times of the 2,4-disubstituted-5-fluoropyrimidine derivatives and finasteride to be tested are approximately 0.87 min and 1.53 min, respectively. There are no co-eluting interference peaks at the retention times. Endogenous substances in plasma do not interfere with the detection of the 2,4-disubstituted-5-fluoropyrimidine derivatives and finasteride to be tested.
[0083] Standard curve and detection limit
[0084] The linear range of the 2,4-disubstituted-5-fluoropyrimidine derivatives to be tested in the plasma samples is 1.000-500.0 ng / mL. The typical linear regression equation of the standard curve of the 2,4-disubstituted-5-fluoropyrimidine derivatives to be tested is: y=0.067x-0.00189. The peak area ratio of the chromatographic peaks of the 2,4-disubstituted-5-fluoropyrimidine derivatives to be tested and finasteride in the plasma samples to be tested can be substituted into the standard curve for calculation to obtain the content of the 2,4-disubstituted-5-fluoropyrimidine derivatives to be tested in the plasma samples to be tested.
[0085] The lowest point of the linear range of the standard curve was taken as the lower limit of quantification. The concentration of the 2,4-disubstituted-5-fluoropyrimidine derivative to be tested in the lower limit of quantification sample was 1.000 ng / mL, and the signal-to-noise ratio was 19.8. The detection limit was calculated to be approximately 0.1515 ng / mL based on the signal-to-noise ratio of 3, and the amount of the analyte on the detection limit column was calculated to be 0.1 pg based on the dilution factor of 20 and the injection volume of 2 µL.
[0086] Precision and accuracy of the method
[0087] The specific data of the precision and accuracy of the concentration of the 2,4-disubstituted-5-fluoropyrimidine derivatives to be tested in plasma are shown in Table 4. The intra-batch precision, inter-batch precision and accuracy of the quantitative lower limit samples were all between 4.55% and 10.60%, and the intra-batch precision, inter-batch precision and accuracy of the QC samples at the other concentration levels were all between 2.49% and 6.51%, all meeting the acceptance criteria.
[0088] Table 4 Precision and accuracy data (n=6)
[0089]
[0090] Recovery rate
[0091] According to the recovery determination method, in the LQC, MQC and HQC concentration level samples: the extraction recoveries of the 2,4-disubstituted-5-fluoropyrimidine derivatives to be tested were 111.4%, 101.3% and 96.1%, respectively; the average recovery of finasteride was 111.0%. The recoveries of the 2,4-disubstituted-5-fluoropyrimidine derivatives to be tested and finasteride were within the generally acceptable range (85%~115%), indicating that the protein precipitation method of the present invention has no effect on the concentration detection of the 2,4-disubstituted-5-fluoropyrimidine derivatives to be tested in plasma when used for plasma sample pretreatment.
[0092] Matrix Effects
[0093] The matrix factors of the internal standard normalized for the 2,4-disubstituted-5-fluoropyrimidine derivatives under LQC and HQC concentration levels were 113.0% and 105.0%, respectively, and the RSDs were 7.08% and 1.90%, respectively. The above results show that the plasma matrix effect does not interfere with the accuracy of the concentration or content detection of the analyte.
[0094] Stability test
[0095] The test results of the stability of the tested 2,4-disubstituted-5-fluoropyrimidine derivatives in plasma samples (n=6) are shown in Table 5. The results show that the tested 2,4-disubstituted-5-fluoropyrimidine derivatives are stable under the conditions investigated.
[0096] Table 5 Stability test data (n=6)
[0097]
[0098] 4 In vivo pharmacokinetic studies
[0099] The validated method was used to detect the 2,4-disubstituted-5-fluoropyrimidine derivatives in plasma to evaluate their pharmacokinetic characteristics. A healthy SPF Sprague-Dawley (SD) rat was intravenously administered with a single dose of 5 mg / kg of the test compound. The plasma drug concentration-time curve was as follows: Figure 5 The sensitivity of the detection method of Example 1 can fully describe the pharmacokinetic characteristics, and the selection of the linear range is close to the concentration level of the actual sample. The established method is successfully applied to the detection of the concentration of 2,4-disubstituted-5-fluoropyrimidine derivatives in plasma.
[0100] In summary, the detection method of the present invention has been fully validated by methodology, and has high sensitivity, precision, accuracy, and fast analysis speed, which meets the analysis requirements of non-clinical and clinical research work of innovative drug molecules 2,4-disubstituted-5-fluoropyrimidine derivatives (CAS No.: 2968523-32-0).
[0101] Example 2 Optimization process of the method in Example 1
[0102] (1) Screening and optimization of plasma sample processing methods
[0103] In the treatment of plasma samples, the purpose of adding an organic solution containing an internal standard is to precipitate proteins and introduce internal standards. The present invention screens and optimizes the type and concentration of the internal standard and the volume of the organic solution. The finasteride in the acetonitrile and / or methanol solution is 0.5 and 2.0 ng / mL, and the volume ratio of the organic solution containing finasteride to the plasma sample is 1:1 to 1:15. After the experiment, it is finally determined that the concentration of finasteride in the acetonitrile and / or methanol solution is 2.0 ng / mL, and when the volume of the plasma sample is 20 μL, the volume ratio of the organic solution containing finasteride to the plasma sample is 1:10, and the protein precipitation effect is the best. When diluting with water, the amount of water added after screening and centrifugation is 0.5 to 2 times the volume of the supernatant.
[0104] (2) Screening and optimization of chromatographic columns
[0105] Different types of chromatographic columns have been tried, such as Hypersil GOLD™ C8 (2.1mm×50mm, 2.5µm), ACEExcel 2 C18 (2.1mm×50mm, 2µm), ACQUITY UPLC BEH C18 (2.1mm×50mm, 1.7µm), XBridge®C18 (2.1mm×50mm, 2.5µm) and XBridge®C8 (2.1mm×50mm, 2.5µm), etc. These columns have their specific applications and advantages in drug analysis. Based on the preliminary screening, the key performance indicators of different chromatographic columns such as chemical stability, column efficiency, selectivity and compatibility with mass spectrometry were further compared, and experimental verification showed that although some chromatographic columns performed well in some aspects, they were not ideal in separation efficiency or analysis time. However, when the XBridge® BEH C8 column in Example 1 was used, with an inner diameter of 2.1 mm, a length of 50 mm, and a filler particle size of 2.5 µm, the analyte had a sharp chromatographic peak on the column, and the overall chromatographic operation was fast, with an analysis cycle completed in just 5 minutes, which is of great significance for improving experimental efficiency and reducing costs. After repeated experiments, it was confirmed that the XBridge® BEH C8 column also performed well in terms of repeatability and stability, which is crucial to ensuring the reliability of experimental results.
[0106] (3) Screening and optimization of mobile phase
[0107] Selection of organic phase: Two commonly used organic solvents were initially considered: methanol and acetonitrile. Methanol is widely used due to its low viscosity and good UV absorption properties. Acetonitrile is used to improve the separation of certain compounds due to its high polarity.
[0108] Selection of aqueous phase: In order to improve the shape of the chromatographic peak and increase the separation efficiency, the pH value of the mobile phase can be adjusted by formic acid or acetic acid, which is crucial for the separation of certain acid-base sensitive compounds; ammonium formate and ammonium acetate can be used as additives to the aqueous phase to increase the ionic strength, which helps to improve the retention and separation of certain ionic compounds.
[0109] After a series of experimental adjustments and optimizations, it was finally determined that mobile phase A was an aqueous solution containing 0.01% formic acid and 5mM ammonium formate, and mobile phase B was methanol. This combination provides the best peak shape, ensuring that the chromatographic peaks are sharp and symmetrical, thereby improving the sensitivity and accuracy of the analysis. As shown in Example 1, the mobile phase combination selected by the present invention is compatible with the mass spectrometry system without causing additional background noise or ion suppression, and the selected mobile phase shows good stability and repeatability in multiple experiments, which is very important for ensuring the reliability and reproducibility of the experimental results.
[0110] (4) Optimization of gradient elution program
[0111] Prior to optimization, an attempt was made to use isocratic elution, where the composition of the mobile phase remained unchanged throughout the analysis. Although this method is simple to operate, it cannot effectively separate multiple compounds in complex samples. In order to improve separation efficiency and shorten analysis time, a gradient elution procedure was introduced. By gradually changing the composition of the mobile phase, the retention time of different compounds can be more effectively controlled, thereby achieving better separation.
[0112] By designing different gradient curves, including linear, convex, concave, etc., to meet the separation requirements of the compounds and ensure that problems such as method carryover do not occur, the starting ratio, change rate and final ratio of the gradient are adjusted and optimized, and finally the gradient elution program described in Table 2 is determined, which can quickly separate the analytes while maintaining the sharpness and symmetry of the chromatographic peaks.
[0113] (5) Optimization of autosampler temperature and column temperature
[0114] The separation effect of the analytes was investigated under the same gradient, different autosampler temperatures (-5℃, 5℃ and no temperature control) and different column temperatures (20℃, 30℃ and 40℃). The results showed that the separation effect of the analytes was best when the autosampler was at 5℃ and the column temperature was at 40℃, and adjusting the autosampler at 0-10℃ and the column temperature at 30-45℃ met the requirements.
[0115] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. It should be pointed out that a person skilled in the art can make several improvements and modifications without departing from the technical principles of the present invention, and these improvements and modifications should also be regarded as within the scope of protection of the present invention.
Claims
1. A method for detecting the concentration of 2,4-disubstituted-5-fluoropyrimidine derivatives in plasma, characterized in that: The following steps are involved: Pretreatment: adding an organic solution containing an internal standard to the plasma sample to precipitate protein, taking the supernatant after centrifugation, and diluting with water to obtain the test sample; the internal standard is finasteride, and the organic solution containing the internal standard includes a methanol solution containing finasteride and / or an acetonitrile solution containing finasteride; Injection test: Liquid chromatography-tandem mass spectrometry is used to inject the test sample for test, wherein the chromatographic conditions and mass spectrometry conditions are as follows: Chromatographic conditions: XBridge®BEH C8 column, gradient elution, autosampler temperature 0-10°C, column temperature 30-45°C, mobile phase A is an aqueous solution containing 0.01% formic acid and 5 mM ammonium formate, mobile phase B is methanol; Mass spectrometry conditions: electrospray ion source, positive ion detection, monitoring mode of multiple reaction monitoring, spray voltage of 5500 V, ion source temperature of 500 °C; The chemical structure of the 2,4-disubstituted-5-fluoropyrimidine derivative is 。 2. The method according to claim 1, characterized in that In the pretreatment step, the volume of the plasma sample is 20 to 100 µL, the volume ratio of the plasma sample to the organic solution containing the internal standard is 1:1 to 1:15, and the content of the 2,4-disubstituted-5-fluoropyrimidine derivative to be tested in the plasma sample is 1.000 to 500.0 ng / mL.
3. The method according to claim 2, characterized in that In the pretreatment step, the volume of the plasma sample is 20 μL, and the volume ratio of the plasma sample to the organic solution containing the internal standard is 1:
10.
4. The method according to claim 1, characterized in that: In the pretreatment step, the amount of water added after the centrifugation is 0.5 to 2 times the volume of the supernatant.
5. The method according to claim 4, characterized in that In the pretreatment step, the volume of water added after the centrifugation is equal to the volume of the supernatant.
6. The method according to claim 1, characterized in that In the pretreatment step, the concentration of finasteride in the organic solution containing the internal standard is 2.000 ng / mL.
7. The method according to claim 1, characterized in that In the chromatographic conditions, the specifications of the XBridge® BEH C8 chromatographic column are 2.1 mm×50 mm, 2.5 µm.
8. The method according to claim 1, characterized in that In the chromatographic conditions, the temperature of the automatic sampler was 5°C and the column temperature was 40°C.
9. The method according to claim 1, characterized in that: In the chromatographic conditions, the gradient elution program is set as follows: , The percentages of mobile phase A and mobile phase B are by volume.
10. The method according to claim 1, characterized in that In the mass spectrometry conditions, gas 1 is 50psi, gas 2 is 55psi, curtain gas is 35psi, collision activated dissociation is 8psi, and residence time is 300ms; the quantitative analysis ion pair m / z of the 2,4-disubstituted-5-fluoropyrimidine derivative to be tested is 405.3→134.2, the collision energy is 60eV, and the declustering voltage is 130V; the quantitative analysis ion pair m / z of the internal standard finasteride is 373.1→305.2, the collision energy is 40eV, and the declustering voltage is 100V.
Citation Information
Patent Citations
2, 4-disubstituted-5-fluoropyrimidine derivative as well as preparation method and application thereof
CN116514779A
Single-composition traditional Chinese medicine preparation, and preparation method and application thereof
CN102240301A
Hapten and application thereof in detection of tripdiolide and triptolide
CN111440185A
